We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Sample Screened for Cystic Fibrosis-Causing Mutations

By LabMedica International staff writers
Posted on 31 Aug 2010
A new diagnostic test simultaneously screens a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours.

The comprehensive and flexible cystic fibrosis (CF) test will be used to screen potential parents to determine if they are carriers of CF-causing gene mutations, and as an aid in newborn screening and confirmatory diagnostic testing in newborns and children.

The xTAG Cystic Fibrosis 60 Kit v2 detects CFTR gene mutations including the 23 CFTR gene mutations and four variants (polymorphisms) recommended by the American College of Medical Genetics (ACMG) and American College of Obstetricians and Gynecologists (ACOG); 37 additional common North American mutations, including 20 mutations that are found within Hispanic and African-American populations are also detected

Luminex Corporation (Austin, TX, USA) introduced the xTAG Cystic Fibrosis 60 Kit v2. The test recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA; Silver Spring, MD, USA).

"The launch of our new xTAG Cystic Fibrosis 60 Kit v2 is a great achievement in cystic fibrosis testing," said Patrick J. Balthrop, president and CEO of Luminex. "This cleared test has the most comprehensive genetic mutation coverage available today, featuring mutations found among Caucasians as well as those that are more commonly found in other ethnic populations. It will give doctors the ability to screen children and potential parents of many ethnicities for CF."

CF is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. To date, more than 1,500 of these mutations have been discovered. More than 10 million Americans are symptomless carriers of CF-causing gene mutations and approximately 30,000 Americans suffer from the condition. It is a common genetic disorder that causes the body to produce thick mucus that can clog the lungs and affect the digestive system.

Luminex Corporation develops, manufactures, and markets biologic testing technologies with applications throughout the diagnostic and life sciences industries.

Related Links:
American College of Medical Genetics
American College of Obstetricians and Gynecologists
Luminex Corporation
U.S. Food and Drug Administration


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Hemacytometer Cover Glasses
Propper Hemacytometer Cover Glasses
New
Lab Autoclave
T-Lab Eco

Latest Molecular Diagnostics News

POC Sepsis Test Delivers Fast, Accurate and User-Friendly Results in Critical Care Settings

Experimental Blood Test Improves Detection of Early-Stage Pancreatic Cancer

Simple Blood Draw Helps Diagnose Lung Cancer 10 Times Faster